SCHEMBL20500415

SCHEMBL20500415

CC(C)(C)OC(=O)NC1CCN(c2ccnc(N)c2C=O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 1/20 0.48
▸ SKP1 P63208 1/20 0.48
▸ SKP2 Q13309 1/20 0.48
▸ MAP4K4 O95819 2/20 0.44
▸ PIM1 P11309 1/20 0.42
▸ PIM3 Q86V86 1/20 0.42
▸ PIM2 Q9P1W9 1/20 0.42
▸ OPRM1 P35372 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ OPRK1 P41145 1/20 0.42
▸ OGFRL1 Q5TC84 1/20 0.42
▸ PDE10A Q9Y233 1/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ JAK1 P23458 2/20 0.41
▸ CFTR P13569 1/20 0.41
▸ DRD2 P14416 2/20 0.41
▸ KCNA3 P22001 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ CTSK P43235 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20500390 0.89 CKS1B (0.50) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL20500373 0.88 CKS1B (0.49) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL30078465 0.88 CKS1B (0.49) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL20500436 0.86 CKS1B (0.48) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL20500387 0.85 CKS1B (0.47) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL21810307 0.85 CKS1B (0.47) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL4960681 0.83 MAP4K4 (0.48) CKS1BSKP1SKP2MAP4K4PIM1
SCHEMBL20500353 0.83 CKS1B (0.45) CKS1BSKP1SKP2PIM1PIM3
SCHEMBL17531192 0.82 CKS1B (0.54) CKS1BSKP1SKP2MAP4K4PIM1
SCHEMBL20500337 0.81 TSHR (0.49) JAK2JAK1CTSKTYK2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072598-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-07-27 — — US disclosed
WO-2018170284-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2018-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072598-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 CKS1B 3617/4885SKP1 4341/4885SKP2 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback